Recombinant Human Growth Hormone In Paediatric Inflammatory Bowel Disease: University Short Term Effects On Bone Biomarkers and Long Term Effects On Bone And Lean Mass

M A Altowati¹, S Shepherd¹, P McGrogan², RK Russell², SF Ahmed¹, SC Wong¹

¹ Developmental Endocrinology Research Group, Royal Hospital for Sick Children, Glasgow ; ² Department of Gastroenterology, Royal Hospital for

Sick Children, Glasgow, United Kingdom

Background

Abnormalities in skeletal health and body composition have been reported in children with IBD. The use of rhGH may lead to improvement in linear growth in children with IBD. Given the anabolic effects of GH, it is possible that rhGH therapy may lead to improvement in bone mass and body composition in these children. However, the effect of rhGH on bone biomarkers as well as bone density in children with IBD remains unclear.

Objectives To investigate the effects of rhGH on bone and lean mass in paediatric IBD from bone biomarkers and DXA bone mineral density and .

Methods

Results contd

Table 2: Disease Biomarkers and Inflammatory Cytokines

	T+0 (n,12)	T+6 (n,12)	T+12 (n,8)	T+24 (n,8)
ESR (mm/hr)	21.0 (1.0,51)	22.0 (4,50)	22.0 (3,30)	17 (5,48)
CRP (mg/l)	7.0 (7.0,42)	7.0 (7.0,38)	7 (7,26)	9 (3,35)
ALB (g/l)	35.5 (20,40)	36.0 (25,41)	37 (19,41)	37 (30,39)
Platelets (10/I)	398 (272,748)	357 (248,507)	377 (225,504)	375 (200,453)
TNFα (pg/ml)	3.0 (2.8,100.6)	3.4 (3.1,5.3)	NA	NA
IL6 (pg/ml)	3.0 (3,17.5)	3.0 (3.0,28.6)	NA	NA
IL1β (pg/ml)	11.7 (3,796.7)	9.95 (1.3,476)	NA	NA
IFNα (IU/ml)	97.5 (25.1,575.4)	98.5 (25.9,116.3)	NA	NA
IFNγ (pg/ml)	26.9 (20,894.6)	24.9 (4.7,76.4)	NA	NA




Bone biomarkers and inflammatory cytokines were evaluated in 12 children,11 crohn's disease (CD) (10M), median age 14.4yr (8.9,16.2); median disease duration 3.7yr (0.6,10.1)who received rhGH (0.067 mg/kg/day). Eight received rhGH for 24 months and had DXA evaluation. Results were reported as median (range) at baseline (T+0), six months (T+6), twelve months (T+12) and 24 months (T+24).

Results							
Table 1: Chang	e in Therapy,	Anthropometric and Puberty					
	T+0	T+6	T+12	T+24			
	(n,12)	(n,12)	(n,8)	(n,8)			
Prednisolone	4/12	1/12	1/8	1/8			
Anti TNF therapy	1/12	2/12	2/8	2/8			
Surgery	1/12	0/12	1/8	0/8			
Enteral nutrition	4/12	1/12	1/8	0/8			
BMI SDS	-0.4	-0.6	-0.3	-0.8			
	(-1.9,0.3)	(-1.6,0.4)	(-2.3,0.7)	(-1.7,1.5)			
Ht SDS	-2.3	-1.8	-1.4	-0.9			
	(-3.3,-1.2)	(-3.0,-1.1)*	(-2.9,-0.8)*	(-2.4,-0.2)*			
Tanner stage 1	2/12	2/12	2/8	1/8			

Long Term Effects On Bone Density And Lean Mass- 24 Months

Figure 3: DXA LS BMD SDS



Tanner stage 2-3	7/12	5/12	1/8	1/8
Tanner stage 4-5	3/12	5/12	5/8	6/8


Short Term Effects On Bone Biomarkers- 6 Months

Figure 1: Markers of Osteoblastic Function

rhGH for 6 months

Procollagen type I N-terminal propeptide (PINP) and receptor activator of nuclear factor-Kb ligand (RANKL)

↔ Osteoprogeterin (OPG) and bone alkaline phophatase (Data not shown)



LS BMD SDS for bone age

LS BMD SDS for height

rhGH for 24 months

rhGH for 24 months

↔ total body (TB) BMD SDS adjusted for bone age or height and TB bone area adjusted for height centile (Data not shown).

Figure 4: DXA Lean mass(LM) for height centile





Figure 2:Markers of Osteoclastic Function

rhGH for 6 months collagen type 1 cross linked c-telopeptide (CTX)



Conclusion

In this preliminary study, short term treatment with rhGH in paediatric IBD was associated with increase in bone turnover but longer term treatment did not lead to improvement in bone density and lean mass.

rhGH therapy should not be used primarily to improve bone mass in paediatric IBD until results of further studies are available.

Future studies of rhGH should include assessments of bone geometry and microarchitecture in these children.